# Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

> **NCT01172821** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1032 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** tiotropium Respimat® low dose
- **DRUG:** placebo
- **DRUG:** tiotropium Respimat® high dose
- **DRUG:** 50 mcg salmeterol HFA MDI
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01172821
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 1032 (ACTUAL)
- **Last updated:** 2014-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01172821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01172821, "Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01172821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*